Research Project
CANDY’s innovation is to test, for the first time, if those disorders and their common mental and bodily co-symptoms, are caused by combinations of common and rare genetic variants and immune activation acting at different ‘sensitive periods’.
CANDY’s innovation is to test, for the first
time, if those disorders and their common mental and bodily co-symptoms, are caused by
combinations of common and rare genetic variants and immune activation acting at different
‘sensitive periods’. CANDY is short for Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy. Many developmental brain
conditions co-occur, meaning that if a person has one of those disorders they are quite likely to also have
another one. For instance, in autism spectrum disorder, the combination of intellectual disability and
epilepsy is associated with a reduction in lifespan of about 20 years; and an economic cost that is greater
than cancer, stroke, or dementia. Yet, the research spend on neurodevelopmental diseases is less than 1% of
the spending on cancer, stroke and dementia. Noldus will further develop its innovative tools for neuroscience research
using animal models to support the research in this project. Specifically it will both develop better
tracking in its EthoVision XT software as well as improve the integration of physiology and behavioral
measurements in EthoVision. Radboud University Medical Centre, Nijmegen (Project Coordinator), King's
College London, Birkbeck, University of London, Institut Pasteur, University of Basel, University of
Groningen, University of Ghent, Karolinska Institute, Assistance Publique des Hôpitaux de Paris, INSERM,
University of Ulm
CEA, ADDISS, Autism Europe, Noldus Information Technology, ARTTIC This project is funded by the Horizon 2020 research program of the European
Union under grant number 847818. To find out more, you can contact us or visit the project website.
CANDY
RESEARCH PROJECT
CANDY
The role of Noldus
Partners
Funding
More information